Key result
Colchicine demonstrates established benefits in pericarditis and emerging evidence for CAD and AF.
Why the study?
Inflammation plays a major role in atherosclerosis, and colchicine has shown beneficial effects across multiple cardiovascular diseases, warranting a summary of its mechanisms and clinical trial evidence.
Colchicine is an attractive, low-cost anti-inflammatory therapeutic option with established benefits in pericarditis and emerging evidence in coronary artery disease, atrial fibrillation, and postcardiotomy syndromes.
Supports established pericarditis use via low cost and safety; leaves optimal CAD and AF roles open pending further trials.
Colchicine has been used since ancient times for gout and familial Mediterranean fever. Inflammation plays a major role in the pathogenesis of atherosclerosis thus paving a way for the use of anti-inflammatory drugs in the management of cardiovascular diseases (CVD). The role of colchicine in the management of pericarditis has been well established. It has been evident from clinical trials the beneficial effects of colchicine in various cardiovascular conditions such as coronary artery disease, atrial fibrillation, and postcardiotomy syndromes. The most frequently used dose of colchicine is 0.5 mg once a day, with duration varying according to clinical condition. The widespread availability, low cost and acceptable side effect profile has made colchicine an attractive therapeutic option. The aim of this article is to summarize colchicine’s mechanism of action and evidence from various trials of its use in CVD in the current era.
No takes yet. Share an insight, caveat, or question.
Lavanya et al. (2023) conducted a review in Cardiovascular diseases. Colchicine was evaluated. Colchicine, typically dosed at 0.5 mg daily, has established benefits in pericarditis and emerging evidence for use in coronary artery disease and atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: